Table 4.

Minimum inhibitory concentrations of azoles for Cryptococcus neoformans and Cryptococcus gattii species complexes isolates from Latin America, according to the molecular type. Non-wild-type minimum inhibitory concentrations are underlined.

		Fluconazole (µg/mL)		Itraconazole (µg/mL)		Voriconazole (µg/mL)		Posaconazole (µg/mL)
MT	n	Range	GM	Range	GM	Range	GM	Range	GM	Ref.
VNI	99	0.125–8	0.521	<0.016–0.25	0.026	<0.016–0.125	0.022	<0.016–0.125	0.027	[77] 1
	75	0.125–32	2.971							[116] 1
	19	0.25–8	-	<0.016–0.5	-	<0.016–0.25	-	0.016–0.125	-	[17] 1
	51	0.25–16	7.22							[85] 1
	18	0.5–16	-	0.06–0.25	-	0.03–1	-			[89] 1
	17	1–16	4.34	0.03–0.25	0.09	0.06–0.5	0.28			[58] 1
	1	1	-							[91] 6
	26	2–8	4.57	0.03–0.25	0.07					[79] 1
	7	2–48	-	0.125–0.5	-					[65] 3
	19	4–>64	-							[63] 2
	1	32	-							[72] 3
VNB	6	4–8	6.86							[85] 1
VNII	2	1–2	1.414							[116] 1
	14	1–8	2.5							[85] 1
VNIII	4	2–4	2.378							[116] 1
VNIV	36	0.125–64	-							[35] 4
VGI	1	2	-							[123] 1
	1	2	-	0.125	-	0.063	-	0.125	-	[124] 1
	4	4–8	5.3							[54] 2
	1	8	-	0.25	-	0.5	-			[60] 1
VGII	18	0.5–16	2.0785	0.031–0.25	0.0994	0.031–0.25	0.0853	0.031–0.25	0.0853	[66] 1
	8	0.5–16	4	0.125–0.25	0.1777	0.0031–1	0.148			[89] 1
	7	1–8	-	0.03–0.125	-					[90] 1
	10	1–16	7.46	0.03–0.5	0.22	0.06–0.5	0.28			[58] 1
	50	1–64	12.2							[54] 2
	2	4–16	-	1	-	0.12–1	-			[81] 1
	10	4–64	25.82							[85] 1
	4	8–32	19	0.125–0.5	0.29					[79] 1
	1	8	-	0.25	-	0.5	-			[59] 1
	1	24	-	0.5	-					[65] 3
VGIII	54	1–128	8.239	<0.015–0.125	0.061	<0.008–1	0.033	0.015–0.25	0.057	[32] 5
	2	4–16	-	0.125	-	0.06–0.125	-			[117] 2
	1	32	-	0.25	-	0.25	-	0.5	-	[134] 1

Methodology to determine antifungal susceptibility: ¹ M27-A3 guidelines of the CLSI, ² AFST-EUCAST method E.Def.7.2., ³ E-test strips, ⁴ Casitone broth microdilution method, ⁵ Sensititre YeastOne plates, and ⁶ Vitek-2. MT: molecular type. n: number of studied isolates. GM: geometric mean.